CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

Wonder drugs’ like Ozempic, hailed by celebrities and some medics as a cure for an ever-mounting list of conditions, most notably obesity and diabetes, have started to appear in darker headlines ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...

A Nova radio host has admitted live on-air to taking a weight loss drug popular with celebrities that costs an arm and a leg ...

A charity boss who once tipped the scales at more than 28st says weight-loss injections have changed the way he thinks about ...

Michael 'Wippa' Wipfli made a bombshell admission live on-air on Wednesday that he was taking an expensive celebrity weight ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

The shortage, which began in December 2022 for Mounjaro and extended to Zepbound ... will further strengthen our process development and scale up our manufacturing capabilities to speed delivery ...